Study Designs and Statistical Methods for Assessing the Genetic Architecture of Disease

FDA’s Division of Drug Information in the Center for Drug Evaluation and Research (CDER) is excited to present a series of educational webinars targeting the needs of all health care professionals and students, including physicians, physician assistants, nurses, pharmacists, and pharmacy technicians.

Osteosarcoma is the most common type of primary bone cancer affecting adolescents and children attributed to rapid bone growth and turnover with a peak incidence at 18 years old. it is a rare incurable and often fatal disease. The current osteosarcoma treatments include standard chemotherapy, limb salvage surgery or amputation. The 5-year relative survival rate is 70% for localized forms, however, metastasis is present in about one fifth to one-quarter of patients at diagnosis, which then contributes to a 5-year survival rate of around 20%. The survival statistics have remained constant with no advances in treatment options for decades highlighting the need for new therapeutic options.

In this webinar, Anders Högdin, Senior Sales Director at Recipharm discusses the common challenges companies encounter during upscaling. He also outlines the key considerations during the medicinal and process chemistry planning phases, the regulatory requirements and the steps companies can take to streamline the process.

In association with pharmaphorum, Tag discusses what pharmaceutical marketers can to do stay ahead of the evolving customer journey.